StockData

Q32 Bio vs Xilio Therapeutics

QTTB and XLO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How QTTB and XLO compare

Q32 Bio is the larger company, worth 5.9 times as much as Xilio Therapeutics ($257M against $43.6M).

Xilio Therapeutics scores higher on the StockData Score (11 against 8 for Q32 Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricQTTBXLO
Size and price
Market cap$257M$43.6M
Share price$8.63$7.54
Change, 1 year300%−23.8%
Change, 5 years−90.8%−97.3%
Beta (5Y)−0.980.03
Employees2476
StockData Score
Total score811 (better)
Valuation score03 (better)
Growth score11
Performance score12 (better)
Health score6 (better)5
Dividend score00
Valuation
P/S–0.7×
P/B2.4×0.6× (better)
EV/EBITDA7.0×–
FCF yield–−141%
Fair value–$37.97
Margin of safety–80.1%
Growth
Revenue growth (TTM)–327%
Revenue growth, 5Y average81.9%–
Profitability
Operating margin–−48.9%
Net margin–−34.1%
FCF margin–−95.6%
Return on equity72.1% (better)−55.0%
Financial health
Debt / equity0.000.00
Current ratio20.30 (better)4.25
Altman Z-score14.49 (better)−3.02
Piotroski F-score45 (better)
Dividends and buybacks
Buyback yield−4.0%–
Shareholder yield−4.0%0.00% (better)
Ownership
Held by institutions74.6%58.9%
Held by insiders28.9%–
Insider net buying, 12 months$29.5M (better)$38.3K
Short interest, % of float26.4%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.